CDISC Membership

The Food and Drug Administration is renewing its annual membership in CDISC, the foundational data standard critical to its clinical and non-clinical regulatory reviews. This membership ensures the FDA remains at the forefront of global regulatory innovation by actively participating in the development and refinement of industry-wide data standards. Without CDISC, the agency would be unable to modernize its review processes effectively, compromising efficiency, consistency, and interoperability in evaluating medical products. The cost of renewal is minimal relative to the strategic value it delivers, enabling the FDA to maintain leadership in shaping global regulatory data practices. The opportunity is forecasted for posting on May 25, 2026, under NAICS code 813920, and is managed by the FDA's Center for Drug Evaluation and Research. The primary point of contact for program inquiries is cderacquisitions@fda.hhs.gov, while the contracting officer position is currently pending assignment. There is no set-aside classification specified, and the place of performance is not defined, indicating that this is a non-location-specific organizational membership rather than a service contract with physical deliverables. The continued investment in CDISC membership supports the FDA’s mission to uphold the highest standards of data integrity and regulatory science worldwide.